hCG Priming in Women With Low Ovarian Reserve

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this trial is to examine the possible effects of hCG administration for eight weeks prior to IVF/ICSI in women with low ovarian reserve. Primary outcome is the proportion of the antral follicle count that reach the pre-ovulatory stage.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Treatments: Chorionic Gonadotropin

Criteria

Inclusion Criteria:

• Regular menstrual cycle (23-35 days)

• 1.-5. IVF/ICSI cycle at inclusion

• AMH < 6.29 pmol/L (Elecsys® AMH assay)

Exclusion Criteria:

• Uterine malformations or hydrosalpinx

• Submucosal uterine myomas

• Uterine polyps

• Allergy to standard IVF/ICSI medication

• Endometriosis stage III-IV

• Severe comorbidity

• Preimplantation genetic testing

• Testicular sperm aspiration/extraction

• Tumors in the hypothalamus or pituitary gland

• Active thromboembolic disease